<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03327012</url>
  </required_header>
  <id_info>
    <org_study_id>PLQ_2016001</org_study_id>
    <nct_id>NCT03327012</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Panlongqi Tablet in Patients With Knee Osteoarthritis</brief_title>
  <official_title>Efficacy and Safety of Panlongqi Tablet in Patients With Knee Osteoarthritis:A Multicenter, Randomized, Double-blind, Placebo-controlled Parallel Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the efficacy and safety of Panlongqi tablet compared with placebo in the
      treatment of knee osteoarthritis in adults.Half of participants will receive Panlongqi tablet
      in combination,while the other half will receive a Placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The test group will be given Panlongqi tablet 1.2g three times per day,the control group will
      be given placebo 1.2g three times per day. The invention will last 4 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2017</start_date>
  <completion_date type="Anticipated">July 28, 2019</completion_date>
  <primary_completion_date type="Anticipated">March 28, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change from Baseline to week 4 in Visual Analog Scale (VAS)score</measure>
    <time_frame>0 weeks,2 weeks，4 weeks</time_frame>
    <description>VAS scores ranges from 0 to 100, with higher scores indicating heavier pain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change from Baseline to week 4 in Western Ontarioand McMaster Universities Osteoarthritis Index (WOMAC)score</measure>
    <time_frame>0 weeks,2 weeks and 4 weeks</time_frame>
    <description>WOMAC scores ranges from 0 to 96, with higher scores indicating greater disability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change from baseline to week 4 in The Short Form-36 Health Survey (SF-36) scores</measure>
    <time_frame>0 weeks,4 weeks</time_frame>
    <description>SF-36 scores ranges from 0 to 100,it shows the extent of physical function restriction with higher scores indicating greater disability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of adverse events</measure>
    <time_frame>4 weeks</time_frame>
    <description>The number of adverse events related to treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Treatment of Panlongqi Tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients were treated with Panlongqi Tablet.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment of Panlongqi Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients were treated with Panlongqi Placebo Tablet.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment of Panlongqi Tablet</intervention_name>
    <description>Panlongqi Tablet:1.2g,3times a day, oral, for 4 weeks.</description>
    <arm_group_label>Treatment of Panlongqi Tablet</arm_group_label>
    <other_name>capsule A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment of Panlongqi placebo</intervention_name>
    <description>Panlongqi placebo:1.2g,3times a day, oral, for 4 weeks.</description>
    <arm_group_label>Treatment of Panlongqi Placebo</arm_group_label>
    <other_name>capsule B</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1.40-75 years of age (including 40 years and 75 years old), men and women are not limited.

        2. western medicine diagnosis of knee osteoarthritis, clinical classification for primary.

        3.The severity of the imaging classification of K-L≤Ⅲ; 4. treatment VAS pain scores than
        40mm (select the subjects most obvious limb pain symptoms).

        5. informed consent form signed by the patient or legal representative.

        Exclusion Criteria:

          1. within 3 months prior to the trial, the patients were treated within 1 years.

          2. 4 weeks before the treatment, corticosteroids, non steroidal drugs, intra-articular
             injections or other drugs to improve the condition (such as cartilage protective
             agents) were used.

          3. Swelling of the knee joint.

          4. knee synovial crystalline (joint) inflammation, acute inflammatory arthritis,
             rheumatoid arthritis, metabolic bone disease, psoriatic arthritis, septic arthritis,
             systemic lupus erythematosus, Sjogren syndrome, vasculitis and other rheumatic
             diseases caused by inflammatory arthritis and endocrine diseases caused by.

          5. the screening period has any disease history or evidence: The basic of serious
             cardiovascular and cerebrovascular diseases; An active, recurrent peptic ulcer or
             other hemorrhagic disease risk; Sales and other serious diseases of digestive system;
             An associated with malignant tumors, blood, or other serious diseases or system;

          6. patients who are unable to cooperate or cooperate with other mental disorders.

          7. before the screening, any laboratory test indicators meet the following standards: An
             admission of liver and kidney function showed that ALT and AST is more than 1.5 times
             the upper limit of the normal value, Cr is more than 1.2 times the upper limit of
             normal (Reference Research Center laboratory where the range of normal value); An
             other clinically significant laboratory abnormalities, and the researchers judged not
             into the group.

          8. allergic constitution or allergic to test seven tablets, excipients or similar
             ingredients;

          9. doubt or indeed history of alcohol and drug abuse;

         10. pregnant or lactating women or recent planned pregnancies and those who are reluctant
             to use contraceptives;

         11. participants who participated in other clinical trials within the first 3 months.

         12. the researchers believe that patients should not participate in this clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jiang Quan, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guang'anmen Hospital of China Academy of Chinese Medical Sc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jiang Quan, Doctor</last_name>
    <phone>86-010-88001060</phone>
    <email>doctorjq@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Guang'anmen Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100052</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2017</study_first_submitted>
  <study_first_submitted_qc>October 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 31, 2017</study_first_posted>
  <last_update_submitted>October 25, 2017</last_update_submitted>
  <last_update_submitted_qc>October 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</investigator_affiliation>
    <investigator_full_name>Quan Jiang</investigator_full_name>
    <investigator_title>Director，Devision of Rheumatology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

